Introduction
Thrombocytopenia (TP) is a frequent complication after allogeneic stem cell transplantation (SCT). [1] [2] [3] The prognostic significance of the platelet count in patients with chronic graft-versus-host disease (GVHD) has already been emphasized in several previous studies, [3] [4] [5] [6] while among the various etiologies of TP, 2 GVHD is recognized as the most important cause of TP.
Bolwell et al. 7 recently reported that the platelet count at day þ 100 was strongly associated with survival after allogeneic bone marrow transplantation (BMT). However, these approaches have not considered the impact of TP during the period between day þ 30 and þ 90, thereby neglecting transplant-related mortality (TRM) cases before day þ 100, which range from 10 to 25%. Several recent studies have reported a 20 to 26% incidence of TP before day þ 100, 8, 9 where Dominietto et al. 8 suggested that GVHD, together with the donor type, cytogemalovirus infections, and cell dose, may be associated with a delayed platelet recovery after allogeneic SCT, while Bruno et al. 9 found that a late persistent decline in the platelet count, called a secondary failure of platelet recovery, was associated with the development of grade 2-4 acute GVHD, an unrelated donor, stem cell dose, and infection. Thus, to minimize early TRM, a better understanding and careful management of these fragile cases are needed even before day þ 100. Accordingly, the current study attempted to evaluate the prognostic role of the platelet recovery pattern during the period between day þ 30 and þ 90, and its association with the severity of acute GVHD in an allogeneic HLA-identical sibling transplantation setting.
Methods and materials
Transplantation procedure Eighty-five consecutive adult patients who had undergone allogeneic SCT at Kyungpook National University Hospital (Daegu, Korea) between August 1998 and July 2004 were included in this retrospective study. The median age of the patients was 37 years (range, 16-56 years), and the male to female ratio was 63%:37% (n ¼ 54/31). The conditioning regimens consisted of a BuCy-based (n ¼ 55), Cy/ATG (n ¼ 8), and Fludarabine-based regimen (n ¼ 22). Myeloablative and reduced-intensity conditioning was adopted in 63 and 22 patients, respectively. All patients received PBSCs mobilized with cytokine as previously reported. 10, 11 The prophylaxis against acute GVHD consisted of cyclosporin A (CSA; Cipol-N s , ChongKunDang, Seoul, Korea) and methotrexate (MTX), except for five cases that used CSA alone (n ¼ 3) or FK506/MTX (n ¼ 2). The firstline treatment for all patients with acute GVHD consisted of a combination of CSA/FK506 and prednisone (1.2 mg/ Kg/day). In refractory cases, alternative systemic immunosuppressive treatments, including MMF (25 mg/kg/day), FK506, antithymocye globulin (ATG), thalidomide, or PUVA therapy, were provided.
Definitions
Engraftment was confirmed by the peripheral blood counts (myeloid: peripheral absolute neutrophil count of more than 0.5 Â 10 9 /l, megakaryocyte: peripheral platelet count of more than 20 Â 10 9 /l for at least three consecutive days without requiring transfusion). Overall survival (OS) was defined as the time from transplantation until death from any cause. The cumulative incidence of relapse was defined as the time from transplantation until relapse. Nonrelapse mortality (NRM) was defined as the time from transplantation until death from infectious or GVHD-related causes. Acute and chronic GVHD were diagnosed and graded using established criteria. 12, 13 The patients were further subdivided into three distinct groups: those with persistent TP, unstable TP, or non-TP.
(1) Persistent TP was established when the platelet count remained below 50 Â 10 9 /l on day þ 30, þ 60, and þ 90. (2) Unstable TP was established (a) when the platelet count did not recover to a level of 50 Â 10 9 /l by day þ 30 or þ 60, then rebounded to a level of 50 Â 10 9 /l by day þ 60 or þ 90, yet did not reach a level over 100 Â 10 9 /l, or (b) when the platelet count recovered to a level over 50 Â 10 9 /l by day þ 30, yet did not reach a level above 100 Â 10 9 /l by day þ 60 or þ 90.3) When the platelet count never fell below 100 Â 10 9 /l on at least two observational occasions after the engraftment, the patients were stratified as non-TP.
Statistics
The clinical characteristics and transplant outcomes for the stratified platelet recovery groups were compared using a w 2 or Fisher's exact test for the categorical variables and Student's t-test or Mann-Whitney's test for the continuous variables, as appropriate. A multinomial logistic regression analysis was performed to define the factors affecting the platelet recovery pattern based on several variables, such as the disease risk, conditioning regimen, reduced-intensity conditioning, source of the stem cells, CD34 þ cell dose, acute GVHD (grade 0,1 vs 2-4 and grade 0-2 vs 3-4), and development cytomegalovirus reactivation.
Survival analyses of the OS, relapse incidence, incidence of NRM, and infectious events were conducted using the Kaplan-Meier method. Plus, a log-rank test was used for the univariate analyses. The univariate analyses for the OS, cumulative incidence of relapse, NRM, and infectious events were determined using a log-rank test for various parameters, including the platelet recovery patterns, transplant CD34 þ cell doses (o6 vs X6 Â 10 6 /Kg), conditioning (reduced-intensity conditioning vs myeloablative), disease status (standard-vs high-risk), acute GVHD (grade 0-2 vs grade 3,4), and chronic GVHD (yes vs no, extensive vs others). To evaluate the contribution of each component of acute GVHD and the platelet recovery pattern, survival analyses of the OS, NRM, and development of infectious events and extensive chronic GVHD were performed. In terms of the OS, NRM, and incidence of infectious events, the platelet recovery pattern and each component of acute GVHD (i.e. stage 0-2 vs 3,4 for cutaneous GVHD; stage 0,1 vs 2-4 for hepatic GVHD; stage 0-2 vs 3,4 for gut GVHD) were included. Whereas, for the development of extensive chronic GVHD, the platelet recovery pattern, each component of acute GVHD (stage 0-2 vs 3,4 for cutaneous GVHD; stage 0,1 vs 2-4 for hepatic GVHD; stage 0-2 vs 3,4 for gut GVHD), the disease risk, conditioning, and CD34 þ cell dose were all included.
The clinical parameters independently associated with survival in the univariate analyses were also included in multivariate survival analyses using Cox's proportionalhazards regression model by backward conditional procedure. The hazard ratio (HR) and 95% confidence interval (C.I.) were also estimated. Statistical significance is represented by two-tailed P-values. A cut off value of 0.05 was adopted for all the statistical analyses. The statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL, USA).
Results

Kinetics of platelet recovery during early transplant period
Serial measurements of the platelet count revealed that the median platelet count at day þ 30, þ 60, and þ 90 was 78, 74. 5, and 97 Â 10 9 /l, respectively (Table 1) . According to the platelet recovery pattern, 15 patients (18%) were classified with persistent TP, 33 patients (39%) with unstable TP, and 37 patients (43%) as non-TP, out of the total 85 patients ( Figure 1 ).
The time to platelet engraftment was shorter in the non-TP group (median 12 days) than in the unstable TP (16 days) and persistent TP groups (29 days; Po0.001, Figure 2a) . Similarly, the time to neutrophil engraftment was also shorter in the non-TP group (13 days) than in the unstable TP (15 days) and persistent TP groups (17 days; P ¼ 0.006, Figure 2b ).
Transplantation outcomes
The transplantation outcomes are summarized in Table 2 . Sixty-five (77%) out of the total 85 patients experienced acute grade 1-4 GVHD (55 patients: acute grade 2-4 GVHD, 20 patients: acute grade 3,4 GVHD), while 55 (73%) out of 75 patients evaluable for chronic GVHD experienced chronic GVHD and 28 (37%) experienced extensive chronic GVHD.
When last assessed with a median follow-up duration of 340 days (range 29-1987 days; 691 days among survivors with range of 75 to 1987 days), 25 recurrences (29%) and 41 deaths (48%), including 25 NRM cases (29%), were recorded. The causes of death included disease progression (n ¼ 16), infection (n ¼ 16), GVHD-related death (n ¼ 7), and other causes (intracerebral hemorrhage and thrombotic thrombocytopenic purpura with hemolytic uremic syndrome).
The 1-and 2-year OS rates were estimated as 5576% and 4976%, respectively, the 1-and 2-year cumulative incidence rates of relapse were estimated as 3776% and 3976%, respectively, and the cumulative incidence of NRM after 1 and 2 years was estimated as 2975% and 3476%. The cumulative incidence of infectious complications was 1474% on day þ 100 and 4576% on day þ 365 (n ¼ 33), and the median onset of infectious complications was 160 days post transplant (range 20B458 days).
Transplantation outcomes according to platelet recovery patterns The transplantation outcomes according to the platelet recovery pattern are summarized in Table 2 . Differences were noted in the incidence of severe acute GVHD Table 1 Summary of patient characteristics, transplantation procedures, and transplant outcomes before day 100 according to platelet recovery patterns Figure 1 Platelet recovery patterns for three different groups.
(grade 3,4; Po0.001), time to engraftment (Po0.001 for platelet engraftment; P ¼ 0.006 for neutrophil engraftment) and development of NRM (Po0.001) among the 3 groups. Meanwhile, the non-TP group showed the best 2-year OS rate (6678% for non-TP group vs 48710% for unstable TP group vs 1079% for persistent TP group, Po0.0001; Figure 3a ) and lowest incidence of NRM (1176% for non-TP group vs 39711% for unstable TP group vs 8679% for persistent TP group, Po0.0001; Figure 3b ). The non-TP group was also found to be associated with a lower incidence of opportunistic infections (3278% for non-TP group vs 56710% for unstable TP group vs 100% for persistent TP group, Po0.0001; Figure 3c ). However, there was no difference in the relapse incidence among the three groups (P ¼ 0.9849).
When analyzing the causes of death, there was no difference among the three groups as regards death from disease progression, yet a distinct difference in the NRM (Table 2 ). Eight percent of the non-TP group died of NRM, while 33% and 73% of the unstable and persistent TP groups died of NRM, respectively (Po0.001). The causes of NRM also differed among the groups. In the non-TP group, there was only one case (9%) of infection-related NRM, whereas in the unstable and persistent groups, seven (41%) and eight (62%) patients died of opportunistic infections, respectively ( Table 2) .
The results of the multivariate analyses for prognostic factors are shown in Table 3a . In terms of OS, the group stratification according to the platelet recovery pattern was identified as an independent prognostic factor (P ¼ 0.02) together with the disease risk (P ¼ 0.02). For NRM, the platelet recovery pattern was also identified as an independent prognostic factor (P ¼ 0.005). Furthermore, the multivariate analyses for the cumulative incidence of infectious events identified the platelet recovery pattern as an independent prognostic factor (Po0.001), while for the incidence of relapse, a standard risk disease (P ¼ 0.003) and limited chronic GVHD (P ¼ 0.02) were identified as favorable prognostic factors.
Platelet recovery patterns and acute GVHD The incidence of acute GVHD according to the platelet recovery pattern is presented in Table 2 . The development of acute grade 3,4 GVHD was strongly associated with the platelet recovery pattern (Po0.001), although not overall or acute grade 2-4 GVHD. The incidence of severe acute grade 3,4 GVHD at day 30 was 11% in the non-TP group, yet 32% in the unstable TP group and 82% in the persistent TP group (P ¼ 0.0006; Figure 3d ) The multinomial logistic regression analysis to define the factors affecting the platelet recovery pattern revealed a lower number of CD34 þ cells transplanted (P ¼ 0.002) and acute grade 3-4 GVHD (Po0.001) as independent factors. (Tables 1 and 2 ).
As regards the association of the grading system of acute GVHD with the platelet recovery pattern, the non-TP group experienced the lowest rate of grade 3,4 acute GVHD (8%), while the unstable TP group exhibited 24% and the persistent TP group exhibited 60% (Figure 4a) . Similarly, the association of each component of acute GVHD, including gut, cutaneous, and hepatic manifestations, with the platelet recovery pattern also revealed that the persistent TP group included a higher number of patients with a gut manifestation of advanced stage 2-4 GVHD (P ¼ 0.008; Figure 4b) . A cutaneous manifestation of acute GVHD was also associated with the platelet recovery pattern with a weak statistical significance (P ¼ 0.045; Figure 4c ), whereas a hepatic manifestation of acute GVHD was not correlated with the platelet recovery pattern (P ¼ 0.283; Figure 4d ).
Finally, survival analyses were conducted to evaluate the effect of each component of acute GVHD and the platelet recovery pattern on OS, NRM, and the development of infectious events and extensive chronic GVHD. As regards OS and NRM, persistent TP and severe stage 2-4 gut GVHD were associated with poor outcomes. Meanwhile for the incidence of infectious events, persistent TP, severe stage 2-4 hepatic GVHD and severe stage 3,4 cutaneous GVHD were found to be poor risk factors. In addition, the patients with persistent TP and severe stage 2-4 hepatic GVHD showed a higher incidence of extensive chronic GVHD with a high-risk disease compared to the others (Table 3b ).
Discussion
The current study addressed two issues. The first was the clinical significance of the platelet recovery pattern during the early post transplant period (from day 30 to day 90) as regards survival, especially NRM, in HLA-identical sibling transplantation. As such, persistent TP seemed to be strongly correlated to the worst outcome, unstable TP with an intermediate outcome, and non-TP with the best outcome after transplantation. The second issue was the Table 3 (a) Multivariate analysis of cumulative incidence of extensive chronic GVHD, overall survival, nonrelapse mortality, and incidence of infectious events found platelet recovery pattern as independent prognostic factor. (b) Multivariate survival analysis predicting overall survival, nonrelapse mortality, incidence of infectious events, and development of extensive chronic GVHD based on platelet recovery patterns and each component of acute GVHD grading system feasibility of incorporating the platelet recovery pattern into the grading system of acute GVHD, as it has independent prognostic implications besides the other components of acute GVHD, such as cutaneous, gut, or hepatic manifestations.
TP is a frequent complication after allogeneic SCT. The most important mechanism involved in the development of TP after allogeneic SCT is recognized as a GVHD-related event, including autoimmune (ITP-like) destruction, immune regulation, or viral-induced suppression of platelet production.
14 Plus, cytokine-induced TP may offer another explanation for platelet consumption after allogeneic SCT as an nonautoimmune mechanism.2 Several reports have already suggested that TP has a prognostic importance after allogeneic SCT. 4, 7 Plus, Dominietto et al. 8 reported that platelet counts can predict TRM, while Bolwell et al. 7 proposed a screening platelet count measurement at day 100, which has been accepted as a landmark day for the surveillance of chronic GVHD. However, the latter approach can overlook the clinical significance of TP before day 100. Previously, First et al.
1 reported the existence of three patterns of platelet recovery kinetics in an allogeneic BMT setting, non-TP and two distinct thrombocytopenic syndromes, transient and persistent TP. Transient TP, where a normal platelet count (4100 Â 10 9 /l) is initially established by day þ 40, which then diminishes to o10 to 45 Â 10 9 /l on day þ 40 to þ 70 with a subsequent resolution of the TP by day þ 90, has no adverse affect on the prognosis, whereas persistent TP, where a platelet count 4100 Â 10 9 /l is not achieved at any time during the first 4 months post transplant, carries a high mortality and association with severe acute and chronic GVHD. In contrast, the stem cell source in the current study was 86% cytokine-mobilized PBSCs, and the incidence of extensive GVHD with allogeneic PBSCT was 67%, which was higher than in an allogeneic BMT setting. 15 As such, the incidence of TP was also anticipated to be higher in relation to GVHD in an allogeneic PBSCT setting than in a BMT setting.
In the present study, the most common cause of death in thrombocytopenic patients was NRM (73% in persistent TP group vs 33% in unstable TP group vs 8% in non-TP group; Tables 2 and 3A, Figure 3b) , which was consistent with a previous investigation. 7 Moreover, the incidence of opportunistic infections was higher in the thrombocytopenic group than in the non-TP group (100% in persistent TP group vs 56% in unstable TP group vs 32% in non-TP group; Table 2, Figure 3c ). Therefore, these observations would seem to imply that the platelet recovery pattern can identify the risk group for NRM and opportunistic infections. As regards OS, the platelet recovery pattern and disease risk were identified as independent prognostic factors in a multivariate analysis, which was also consistent with previous results. 7 Furthermore, the current study found that a delayed stable platelet recovery was strongly associated with severe acute GVHD (grade 3,4) ( Table 2 , Figures 3d and 4) , and that the platelet recovery pattern reflected the probability of the development of extensive chronic GVHD, OS, NRM, and opportunistic infections when analyzing the data together with the components of acute GVHD grade (Table 3B) . Several studies have already reported that acute GVHD influences the platelet recovery before the development of chronic GVHD. 8, 9 In particular, Dominietto et al. 8 proposed that TP (p50 Â 10 9 /l) was important in identifying the risk group for TRM in patients with grade 2 acute GVHD. 8 Similarly, the current study found that the platelet recovery pattern itself played an independent role in predicting the development of extensive GVHD by suggesting the severity of acute GVHD (Table 3B) . Moreover, the prognostic significance of the platelet recovery pattern in terms of OS, NRM, and the incidence of opportunistic infections insinuate that it could be adopted as a criterion in the acute GVHD grading system.
It is notable that the persistent TP group received lower dose of CD34 þ cells than those with transient or non-TP. In a previous study, 16 the correlation of transplant CD34 þ cell dose and the engraftment kinetics of platelet have been suggested.
The advantages of using the platelet recovery pattern based on serial peripheral platelet counts between day þ 30 and þ 90 are as follows: (1) it is an easy method for predicting the development of extensive chronic GVHD and infectious events, (2) it has a strong correlation with the severity of acute GVHD before the development of chronic GVHD, and (3) it can predict the probability of NRM independent of the risk of relapse.
In conclusion, the platelet recovery pattern between day þ 30 and þ 90 can predict the prognosis of recipients in terms of OS and NRM after HLA-identical sibling transplantation. Persistent TP was found to have the highest risk of NRM and infectious events after SCT. In addition, the platelet recovery pattern was strongly associated with the severity of acute GVHD.
